Search

Your search keyword '"Ortiz, Natasha"' showing total 10 results
Start Over Author "Ortiz, Natasha"
10 results on '"Ortiz, Natasha"'

2. Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells.

Author

Robert, Sacha, Roman Ortiz, Natasha Ivelisse, LaRocca, Christopher J., Ostrander, Julie Hanson, and Davydova, Julia

Subjects
*CANCER stem cells, *BREAST cancer, *ADENOVIRUSES, *ESTROGEN receptors, *SODIUM iodide, *PACLITAXEL, *DISEASE risk factors, *BREAST
Abstract

Adjuvant systemic therapies effectively reduce the risk of breast cancer recurrence and metastasis, but therapy resistance can develop in some patients due to breast cancer stem cells (BCSCs). Oncolytic adenovirus (OAd) represents a promising therapeutic approach as it can specifically target cancer cells. However, its potential to target BCSCs remains unclear. Here, we evaluated a Cox-2 promoter-controlled, Ad5/3 fiber-modified OAd designed to encode the human sodium iodide symporter (hNIS) in breast cancer models. To confirm the potential of OAds to target BCSCs, we employed BCSC-enriched estrogen receptor-positive (ER+) paclitaxel-resistant (TaxR) cells and tumorsphere assays. OAd-hNIS demonstrated significantly enhanced binding and superior oncolysis in breast cancer cells, including ER+ cells, while exhibiting no activity in normal mammary epithelial cells. We observed improved NIS expression as the result of adenovirus death protein deletion. OAd-hNIS demonstrated efficacy in targeting TaxR BCSCs, exhibiting superior killing and hNIS expression compared to the parental cells. Our vector was capable of inhibiting tumorsphere formation upon early infection and reversing paclitaxel resistance in TaxR cells. Importantly, OAd-hNIS also destroyed already formed tumorspheres seven days after their initiation. Overall, our findings highlight the promise of OAd-hNIS as a potential tool for studying and targeting ER+ breast cancer recurrence and metastasis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Author

Miller, Timothy M, Cudkowicz, Merit E, Andrews, Jinsy A, Hesters, Adele, Kermorvant, Hugo, Lacomblez, Lucette, Forestier, Nadine Le, Lenglet, Thimotée, Retail, Maryvonne, Ruiz Del Mar Amador, Maria, Salachas, François, Shotar, Eimad, Sourour, Nader, Babu, Suma, Dorst, Johannes, Froehlich, Elke, Fromm, Andrea, Kandler, Katharina, Langer, Eva, Leichtle, Sarah, Ludolph, Albert, Mayer, Kristina, Michels, Sebastian, Raubold, Sabine, Benatar, Michael, Schuster, Joachim, Weiland, Ulrike, Wiesenfarth, Maximilian, Witzel, Simon, Calvo, Andrea, Canosa, Antonio, Casale, Federico, Chiò, Adriano, Fuda, Giuseppe, Grassano, Maurizio, McDermott, Christopher J, Marchese, Giulia, Moglia, Cristina, Palumbo, Francesca, Salamone, Paolina, Ajiki, Takahiro, Akasaka, Aya, Ando, Masahiro, Arata, Hitoshi, Asuka, Kitamura, Baba, Kosuke, Cochrane, Thos, Bekku, Goichi, Chiba, Tomoya, Date, Yugaku, Eriko, Takeuchi, Hashiguchi, Akihiro, Hatatori, Ritsuko, Hayano, Eri, Hayashi, Yuto, Higashi, Keiko, Higuchi, Eriko, Chary, Sowmya, Hiramatsu, Yu, Horikawa, Rui, Ikenaka, Kensuke, Ishiura, Hiroyuki, Ito, Daisuke, Kawai, Sachiko, Kikuchi, Junko, Kuzuyama, Haruko, Li, Xuehong, Matsumoto, Chika, Chew, Sheena, Matsuura, Eiji, Michizono, Kumiko, Mitsui, Jun, Mitsutake, Akihiko, Mochizuki, Hideki, Nagamatsu, Akemi, Nagano, Seiichi, Nakamura, Tomonori, Naruse, Hiroya, Ogasawara, Asuka, Zhu, Han, Okada, Kensuke, Okamoto, Yuji, Okuno, Tatsusada, Oyama, Satoshi, Ozono, Tatsuhiko, Sakiyama, Yusuke, Sakuishi, Kaori, Seki, Morinobu, Shibata, Shota, Shimizu, Mikito, Wu, Fan, Takahata, Katsunori, Takahito, Yoshizaki, Takashima, Hiroshi, Takeichi, Hiroko, Tashiro, Yuichi, Toda, Tatsushi, Tomizu, Yuki, Tomoya, Wadayama, Ujiakira, Nishiike, Yashita, Daiki, Nestorov, Ivan, Al-Chalabi, Ammar, Alix, James, Bangalore, Priyadarshini, Blackburn, Daniel, Chiwera, Theresa, Clegg, Rosie, Collins, Alexis, Cooper-Knock, Jonathan, Emery, Anna, Franklin, John, Genge, Angela, Graham, Danielle, Green, Louisa, Harvey, Callum, Hobson, Esther, Islam, Mahjabim, Jenkins, Thomas Michael, Kazoka, Mbombe, Kelly, Gillian, Korley, Mercy, Madarshahaian, Daniel, Mayl, Keith, Sun, Peng, McDermott, Christopher John, Radford, Alex, Shaw, Christopher, Shaw, Pamela J, Sidebottom, Joe, Smart, Lynne, Sreedharan, Jemeen, Stone, Ben, Tsironis, Theocharis, Tuddenham, Lee, McNeill, Manjit, Verber, Nick, Wollff, Helen, Young, Stacy, Zis, Panagiotis, Adamo, Ashley, Ahmed, Arubah, Ajroud-Driss, Senda, Alameda, Gustave, Arcila-Londono, Ximena, Fanning, Laura, Baird, Candy, Bazan, Tracy, Berry, James, Bordeau, Jane, Bradford, Wendy, Brook, Nyda, Brown, Lauren, Bucelli, Robert C, Ferguson, Toby A, Buckner, Katherine, Budler, Michael W, Burba, Lindita, Burke, Katherine, Calhoun, Ashley D, Campbell, Sarah, Carey, Judith, Caristo, Irys B, Carty, Simon, Chan, Emmanuel, Fradette, Stephanie, Chaudhry, Vinay, Chen, Ricky, Chow, Saephanh, Clawson, Lora L, Clemens, Mitchell, Cloninger, Suzann E, Coleman-Wood, Krista, Cooper, Thomas N, Cummings, Arlena, Daniels, Jacquelyn, VALOR, DeSaro, Pamela, DeWitt, Michelle, Dedi, Brixhilda, Dempsey, Debbie, Denny, Carol, Doherty, Jenna, Doherty, Leana, Donahue, Megan, Doyle, Michael, Duncan, Jessie, Group, OLE Working, Elman, Lauren, Eloge, Christine M, Echiti, Desirae R, Ferrey, Dominic, Fournier, Christina, Fukumura, Yuriko, Gallagher, Katherine, Garaycoa, Jessica, Garrett, Mark, Gibson, Richard L, Beullens, Lien, Gifford, Ryan, Glass, Jonathan D, Gogol, Danuta, Golden, Shea, Gonzalez, Alexa, Goodman, Ira, Goolsby, Christopher, Goslin, Kimberly, Goulbourne, Michael, Granit, Volkan, Claeys, Kristl, Grignon, Anne-Laure, GuhaRay, Adreeja, Guide, Debra, Gundogdu, Melek Betul, Gutierrez, Gil, Hastings, Debbie, Hayzen, Colleen, Herzog, Hilary, Holloway, Raegan, Jacobs, Gabriel, Claeys, Thomas, Jacobsen, Bill, James, Virginia, Jenkins, Liberty, Jockel-Balsarotti, Jennifer, Johnson, Linda Carol, Jose, Sunil, Joslin, Benjamin, Karanja, Elizabeth, Katz, Jonathan, Keener, Anthony, Couwelier, Goedele, Kittle, Gale, Klein, Sara, Kreple, Collin, Rebecca, Rebecca, Kuenzler, Kuenzler, Kusnir, Jorge, Labbe, Kristen, Lachica-Encinas, Nicolet, Ladha, Shafeeq, Leimer, Lesli, D'Hondt, Ann, Levy, Michael, Levy, Wendy, Li, Yingji, Likanje, Marie-France, Livigni, Rebecca, Locatelli, Eduardo, Luppino, Sarah, Malcolm, Amber, Maragakis, Nicholas, Marin, Horia, Debien, Elisa, Markowitz, Clyde, Markway, Jesse, McCaffrey, Alexandra, McCoy, Arita, McCoy Gross, Kelly, Mehta, Kush, Meyer, Robert, Milan, Jennifer, Miller, Timothy, Miller, Robert G, de Keersmaecker, Sebastiaan, Morales, Francisco, Mosmiller, Elizabeth, Mott, Donovan, Moulton, Kelsey, Murphy, Christine A, Negron, Tirso, Nelson, Cassandra, Newman, Daniel S, Nissinen, Janne Kristoffer, Norman, Andrew, Della Faille, Laetitia, Ohkubo, Takuya, Olney, Nicholas, Ortiz, Natasha, Oskarsson, Bjorn, Pace, Mitchell, Packard, Kathleen, Padgett, Denny, Paganoni, Sabrina, Paredes, Maria E, Parker, Elizabeth, Delmotte, Koen, Partlow, Ann, Pattee, Gary L, Paulett, Jany, Pelot, Antoinette, Pfeifer, Kyle M, Pijanowski, Olivia, Pioro, Erik, Polak, Meraida, Prakash, Ahalya, Previte, Rosemarie, Depoortere, Sofie, Pukenas, Bryan, Quinn, Colin, Ravits, John, Razavi, Ryan, Regan, Tyler, Riley, Kristen M, Roth, Heather, Sanders, Danica, Scalia, Jennifer, Schmidt, Emma, de Velder, Laura, Schwen, Edward, Shah, Jaimin, Shah, Stuti, Shefner, Jeremy, Sheldon, Danielle, Simmons, Karon, Singh, Navneet K, Singleton, Jessica, Smiley, Richard, Smith, William B, Dobbels, Laurens, Smith, Sean, Sotirchos, Elias, Sorenson, Eric, Staff, Nathan, Steele, Julie, Steijlen, Kara, Stirrat, Taylor, Stoica, George S, Strong, Stephanie, Sufit, Robert, Sobue, Gen, Gijs, Jeroen, Sultze, Jane, Swartz, Amy, Szymanski, April, Tay, Anna, Thakore, Nimish, Thiessen, Diana, Thotala, Sukrutha, Trudell, Randall G, Turcotte, Nicole, Turner, Michelle, Horckmans, Simon, Uchil, Alpa, Upadhyay, Vihar, Usman, Uzma, Vallis, Anne, Vaporean-Bussey, Danielle, Vladimirova, Valentine, Weber, Harli, Winbigler, Jennifer, Wojanowski, Heather, Wulf, Charlie, Lamaire, Nikita, Yasek, Julia, Yoo, Stephanie, Zivalic, Hannah, Cole, Alexandra, File, Greta, Foate, Jeremy, Mason, Deborah, Newton, Susan, Roberts, Stephen, Sellwood, Cory Dean, Liessens, Hannelore, Swan, James, Werno, Anja, Zhong, Cathy, Masrori, Pegah, Nysten, Celine, Schotte, Caroline, Serrien, Anouk, Swinnen, Bart, Tilkin, Petra, van Daele, Sien, Van Damme, Philip, Vynckier, Jan, Wouters, Anke, Abrahao, Agessandro, Angle, Mark, Badawy, Mohamed, Berube, Maxime, Bertone, Vanessa, Cooper, Sarah Marie, Dobrowolski, Peter, Fong, Helen, Hannouche, Matthew, Hartley, Denise, Hogan, Michael, Johnston, Wendy, Khalfallah, Yousra, Korngut, Lawrence, Kroetsch, Gina, Letourneau, Justin, Magnussen, Claire, Martinez, Jose, Massie, Rami, Mobach, Theodore, Mookshah, Jahan, Ozelsel, Timur, Parks, Andrea, Petrillo, Janet, Pfeffer, Gerald, Ludolph, Albert C, Pham, Shirley, Phung, Liane, Shiungsun, Rodney, Pi-Shan, Li, Santos, Denizart, Salmon, Kristiana, Saunders, Natalie, Sembinelli, Dylan, Tymkow, Kelsey, Wong, Berchman, Zinman, Lorne, Karlsborg, Merete, Pedersen Lomholt, Therese, Nilsson, Sigrid, Salvesen, Lisette, Skov, Pernille, Svenstrup, Kristen, Bruneteau, Gaelle, Calerencon, Frederic, and Guimaraes Costa, Raquel

Subjects
Adult, drug effects [Recovery of Function], Spinal, Oligonucleotides, blood [Neurofilament Proteins], administration & dosage [Oligonucleotides, Antisense], tofersen, Injections, blood [Amyotrophic Lateral Sclerosis], pharmacology [Oligonucleotides, Antisense], Superoxide Dismutase-1, Double-Blind Method, Neurofilament Proteins, Humans, ddc:610, Antisense, Injections, Spinal, Biomarkers, Recovery of Function, Amyotrophic Lateral Sclerosis, Oligonucleotides, Antisense, blood [Biomarkers], drug therapy [Amyotrophic Lateral Sclerosis], therapeutic use [Oligonucleotides, Antisense], SOD1 protein, human, General Medicine, genetics [Superoxide Dismutase-1], genetics [Amyotrophic Lateral Sclerosis], cerebrospinal fluid [Biomarkers], cerebrospinal fluid [Superoxide Dismutase-1], cerebrospinal fluid [Amyotrophic Lateral Sclerosis]
Abstract

The intrathecally administered antisense oligonucleotide tofersen reduces synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with amyotrophic lateral sclerosis (ALS) associated with mutations in SOD1 (SOD1 ALS).In this phase 3 trial, we randomly assigned adults with SOD1 ALS in a 2:1 ratio to receive eight doses of tofersen (100 mg) or placebo over a period of 24 weeks. The primary end point was the change from baseline to week 28 in the total score on the ALS Functional Rating Scale-Revised (ALSFRS-R; range, 0 to 48, with higher scores indicating better function) among participants predicted to have faster-progressing disease. Secondary end points included changes in the total concentration of SOD1 protein in cerebrospinal fluid (CSF), in the concentration of neurofilament light chains in plasma, in slow vital capacity, and in handheld dynamometry in 16 muscles. A combined analysis of the randomized component of the trial and its open-label extension at 52 weeks compared the results in participants who started tofersen at trial entry (early-start cohort) with those in participants who switched from placebo to the drug at week 28 (delayed-start cohort).A total of 72 participants received tofersen (39 predicted to have faster progression), and 36 received placebo (21 predicted to have faster progression). Tofersen led to greater reductions in concentrations of SOD1 in CSF and of neurofilament light chains in plasma than placebo. In the faster-progression subgroup (primary analysis), the change to week 28 in the ALSFRS-R score was -6.98 with tofersen and -8.14 with placebo (difference, 1.2 points; 95% confidence interval [CI], -3.2 to 5.5; P = 0.97). Results for secondary clinical end points did not differ significantly between the two groups. A total of 95 participants (88%) entered the open-label extension. At 52 weeks, the change in the ALSFRS-R score was -6.0 in the early-start cohort and -9.5 in the delayed-start cohort (difference, 3.5 points; 95% CI, 0.4 to 6.7); non-multiplicity-adjusted differences favoring early-start tofersen were seen for other end points. Lumbar puncture-related adverse events were common. Neurologic serious adverse events occurred in 7% of tofersen recipients.In persons with SOD1 ALS, tofersen reduced concentrations of SOD1 in CSF and of neurofilament light chains in plasma over 28 weeks but did not improve clinical end points and was associated with adverse events. The potential effects of earlier as compared with delayed initiation of tofersen are being further evaluated in the extension phase. (Funded by Biogen; VALOR and OLE ClinicalTrials.gov numbers, NCT02623699 and NCT03070119; EudraCT numbers, 2015-004098-33 and 2016-003225-41.).

Published
2022

5. Conducto con exudado persistente: Causas y manejo clínico

Author

Álvarez Vásquez, José Luis, Guazhima Fernández, María Cristina, and Durán Ortiz, Natasha Carolina

Subjects
Tratamento do canal radicular, Exudado persistente, Endodontics, Endodoncia, Root canal therapy, Tratamiento de conducto radicular, Persistent exudate, Endodontia, Exsudato persistente
Abstract

Objective: The aim of this integrative literature review was to address the causes and clinical management of the canal with persistent exudate or “weeping canal”, which is a clinical entity characterized by the presence of persistent inflammatory exudate in the canal, despite ongoing root canal treatment even after multiple appointments. Methodology: A bibliographic survey was carried out in the Pubmed, Scopus and EBSCO databases, in English and without restriction of publication date. The search terms used in combination were: wet canal, weeping canal, persistent exudate, persistent intracanal exudation, and root canal treatment. Results and conclusion: It is concluded that the main cause described is microbial, in the form of bacterial biofilm or recalcitrant infection. Regarding its clinical management, a series of approaches are available, such as paper points, intracanal dressing, and aspiration systems such as Endovac, while the use of Nd:YAG laser requires more studies to support its clinical use. Objetivo: El objetivo de esta revisión integrativa de la literatura fue abordar las causas y manejo clínico del conducto con exudado persistente o “conducto llorón”, que es una entidad clínica caracterizada por la presencia intraconducto de exudado inflamatorio persistente, pese al tratamiento de conducto en ejecución, incluso después de varias citas. Metodología: Se realizó un levantamiento bibliográfico en las bases de datos Pubmed, Scopus y EBSCO, en idioma inglés y sin restricción de fecha de publicación. Los términos de búsqueda empleados en combinación fueron: conducto húmedo, conducto llorón, exudado persistente, exudación intraconducto persistente y, tratamiento de conducto radicular. Resultados y conclusión: Se concluye que la causa principalmente descrita es la microbiana, en forma de biofilm bacteriano o infección recalcitrante. Respecto a su manejo clínico, existen disponibles una serie de abordajes, como las puntas de papel, la medicación intraconducto y sistemas de aspiración como el EndoVac, en tanto que el empleo de la terapia con láser Nd:YAG requiere de más estudios que respalden su uso clínico. Objetivo: O objetivo desta revisão integrativa da literatura foi abordar as causas e o manejo clínico do ducto com exsudato persistente ou “ducto lacrimejante”, que é uma entidade clínica caracterizada pela presença de exsudato inflamatório persistente no ducto, apesar do ducto tratamento em execução, mesmo após várias consultas. Metodologia: Foi realizado levantamento bibliográfico nas bases de dados Pubmed, Scopus e EBSCO, em inglês e sem restrição de data de publicação. Os termos de pesquisa usados ​​em combinação foram: canal radicular úmido, canal de drenagem, exsudato persistente, exsudato intracanal persistente e tratamento de canal radicular. Resultados e conclusão: Conclui-se que a principal causa descrita é microbiana, na forma de biofilme bacteriano ou infecção recalcitrante. Em relação ao seu manejo clínico, uma série de abordagens estão disponíveis, como pontas de papel, medicação intracanal e sistemas de aspiração como o EndoVac, enquanto o uso da terapia a laser Nd: YAG requer mais estudos para embasar seu uso clínico.

Published
2021

6. Conducto con exudado persistente: causas y manejo clínico

Author

Guazhima Fernandez, Maria Cristina, Alvarez Vasquez, Jose Luis, Durán Ortiz, Natasha Carolina, Guazhima Fernandez, Maria Cristina, Alvarez Vasquez, Jose Luis, and Durán Ortiz, Natasha Carolina

Abstract

Objective: The aim of this integrative literature review was to address the causes and clinical management of the canal with persistent exudate or “weeping canal”, which is a clinical entity characterized by the presence of persistent inflammatory exudate in the canal, despite ongoing root canal treatment even after multiple appointments. Methodology: A bibliographic survey was carried out in the Pubmed, Scopus and EBSCO databases, in English and without restriction of publication date.The search terms used in combination were: wet canal, weeping canal, persistent exudate, persistent intracanal exudation, and root canal treatment. Results and conclusion: It is concluded that the main cause described is microbial, in the form of bacterial biofilm or recalcitrant infection. Regarding its clinical management, a series of approaches are available, such as paper points, intracanal dressing, and aspiration systems such as Endovac, while the use of Nd:YAG laser requires morestudies to support its clinical use.

Published
2021

7. Recomendaciones para el uso racional de la prueba 25-hidroxi vitamina D Policy Brief

Author

Herrera Méndez, Emiliano Mauricio, primary, Yomayusa González, Nancy, additional, Low Padilla, Eduardo, additional, Oliveros Velásquez, Juan David, additional, Mendivelso Duarte, Fredy, additional, Gómez Gómez, Olga Victoria, additional, Castillo Gutiérrez, Ana María, additional, Barrero Garzón, Liliana Isabel, additional, Álvarez Moreno, Carlos Arturo, additional, Moscoso Martínez, Ernesto Augusto, additional, Ruíz Blanco, Pilar Cristina, additional, Luna Ríos, Joaquín Gustavo, additional, Ortiz, Natasha, additional, Herrera, Emilio Mauricio, additional, Guevara Santamaria, Fabian Ricardo, additional, Moreno Gómez, Jairo Enrique, additional, Cárdenas Ramírez, Héctor Mauricio, additional, González González, Camilo Alberto, additional, Jannauth, María José, additional, Patiño Pérez, Adulkarin, additional, Pinto, Diego Alejandro, additional, Acevedo, Juan Ramón, additional, Torres Serrano, Rodolfo Eduardo, additional, Montero Cetina, Jairo Camilo, additional, Acevedo Velasco, Andrés David, additional, Cáceres, Ximena Adriana, additional, Olmos, Jairo Acuña, additional, Arias, Carlos Andrés, additional, Rozo, José Medardo, additional, Castellanos Parada, Jeffrey, additional, López Miranda, Ángelo Mauricio, additional, Pinzón Serrano, Estefanía, additional, Rincón Sierra, Oswaldo, additional, Isaza Ruget, Mario, additional, Suárez Ramos, María del Pilar, additional, Vargas Rodríguez, Johanna, additional, Mejia Gaviria, Natalia, additional, Moreno Marín, Sandra Yadira, additional, García Guarín, Bibiana María, additional, Cárdenas, Martha Lucía, additional, Chavarro, Luis Fernando, additional, Ronderos Bernal, Camila, additional, Rico Landazabal, Arturo, additional, Rosero Olarte, Francisco Oscar Fernando, additional, Medina Orjuela, Adriana, additional, Alfaro Tejeda, Mercedes Teresa, additional, Coronado Daza, Jorge Antonio, additional, Yama Mosquera, Erica, additional, Hernández Sierra, Astrid Patricia, additional, Restrepo Valencia, César Augusto, additional, Álvarez, Javier Arango, additional, Baquero Rodríguez, Richard, additional, Robayo García, Adriana, additional, Carballo Zarate, Virgil, additional, Rodríguez Sánchez, Martha Patricia, additional, Bernal, Dora P., additional, Jaramillo, Laura, additional, Mejía Gaviria, Natalia, additional, and Aroca, Gustavo, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results